[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Nicoletto MO, Dalla Palma M, Donach ME, Gusella M, Cappetta A, Shams M, Marchet A, Nardin M, Pintacuda G, Di Maggio A, Marchesi M, Carli P, Fiduccia P, Artioli G, Nitti D: Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer. Tumori; 2010 Nov-Dec;96(6):918-25
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
  • AIMS AND BACKGROUND: To assess feasibility and toxicity of intraperitoneal administration of cisplatin and paclitaxel, followed by intravenous chemotherapy in pretreated patients with suboptimal ovarian cancer (residuum >1 cm) or primary peritoneal tumor, and suffering from ascites and/or intestinal obstruction.
  • Intravenous chemotherapy was administrated 4 weeks following the last intraperitoneal paclitaxel instillation.
  • Ascites decreased in 11 patients: the median time to first need for paracentesis was 5 months, compared to a median baseline paracentesis of 4 weeks.
  • Intraperitoneal paclitaxel clearance was significantly higher in patients with suboptimal tumor and symptomatic disease than in patients with smaller residual masses and without ascites (P = 0.004).
  • CONCLUSIONS: Intraperitoneal treatment was feasible, and enhanced response to the following intravenous chemotherapy was seen in these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm, Residual / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Ascites / etiology. Carcinoma, Papillary / drug therapy. Cystadenoma, Serous / drug therapy. Feasibility Studies. Female. Humans. Infusions, Intravenous. Infusions, Parenteral. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage. Platinum Compounds / administration & dosage. Retrospective Studies. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21388052.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platinum Compounds; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


2. Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R: Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res; 2001 Nov;7(11):3457-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
  • PURPOSE: The purpose of this study was to analyze the expression of the high- and low-affinity nerve growth factor (NGF) receptors TrkA and p75 in effusions and in primary and metastatic tumors of serous ovarian carcinoma patients, as well as to evaluate their association with clinicopathological parameters and disease outcome.
  • TrkA and p75 showed no association with tumor grade, Fédération Internationale des Gynaecologistes et Obstetristes stage, chemotherapy status, the extent of residual disease, or survival (P > 0.05).
  • TrkA and p75 expression in effusions does not appear to be a predictor of disease outcome in advanced-stage serous ovarian carcinoma.
  • [MeSH-major] Ascitic Fluid / pathology. Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology. Pleural Effusion, Malignant / pathology. Receptor, trkA / genetics. Receptors, Nerve Growth Factor / genetics
  • [MeSH-minor] Animals. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Neoplasm Metastasis. Neoplasm Staging. Nerve Growth Factor / pharmacology. Phosphorylation / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor, Nerve Growth Factor. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11705863.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, Nerve Growth Factor; 0 / Receptors, Nerve Growth Factor; 9061-61-4 / Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkA
  •  go-up   go-down


3. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, Smyth J, Gabra H: Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer; 2004 May 15;100(10):2148-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A review of clinicopathologic features and outcome in women with carcinosarcoma of the ovary (also known as malignant mixed mesodermal tumor [MMMT]) compared with a group of women with serous adenocarcinoma (SAC) of the ovary was conducted.
  • METHODS: Between 1984 and 2002, 1568 patients with epithelial ovarian carcinoma and 70 patients with ovarian carcinosarcoma underwent treatment at the Edinburgh Cancer Centre.
  • Baseline variables were recorded prospectively and response to chemotherapy and progression-free and cause-specific survival between the groups were compared.
  • The objective response rate to platinum-based chemotherapy was found to be significantly lower in patients with carcinosarcoma (25% vs. 60%; P = 0.02).
  • Achieving optimal debulking at the time of initial surgery was found to be a highly significant factor in patients with carcinosarcoma with regard to determining outcome (median survival of 14.8 months for patients with optimally debulked International Federation of Gynecology and Obstetrics Stage III disease vs. 3.1 months for patients with suboptimally/nondebulked Stage III disease; P < 0.001).
  • CONCLUSIONS: Ovarian carcinosarcoma is a distinct entity with a poor prognosis.
  • Patients with carcinosarcoma differ from those with SAC with regard to having an older mean age of onset, an inferior response to platinum-based chemotherapy, and worse progression-free and cause-specific survival.
  • The extent of benefit from chemotherapy is unclear.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / mortality. Cystadenoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139057.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Zhang J, Chen AP, Wang B, Zhao SP, Liu LZ, Dai SZ: [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer]. Ai Zheng; 2008 Dec;27(12):1331-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
  • BACKGROUND & OBJECTIVE: Abnormal expression and activation of epidermal growth factor receptor (EGFR), which is closely related to the recurrence and poor prognosis of ovarian cancer, can promote chemotherapy resistance of tumor cells.
  • Lung resistance protein (LRP), a multidrug resistance protein causing platinum-resistance, is an independent factor in predicting chemotherapy sensitivity to ovarian cancer.
  • This study was to explore the correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer.
  • Correlations of EGFR and LRP to chemotherapy efficacy and survival time of patients with ovarian cancer after operation were analyzed.
  • The positive rates of EGFR and LRP were significant higher in patients with chemotherapy resistance (92.86% and 85.71%) than in those sensitive to chemotherapy (P<0.05).
  • Patients with positive EGFR and LRP and poor short-term efficacy after chemotherapy had short survival time (P<0.01).
  • CONCLUSION: The expression of EGFR and LRP could be used to predict chemotherapy resistance and prognosis of ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Drug Resistance, Neoplasm. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / pharmacology. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080004.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Denschlag D, Ulrich U, Emons G: The diagnosis and treatment of endometrial cancer: progress and controversies. Dtsch Arztebl Int; 2010 Aug;108(34-35):571-7
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnosis and treatment of endometrial cancer: progress and controversies.
  • BACKGROUND: Endometrial carcinoma is the fourth most common type of cancer among women in Germany, with more than 11 000 newly diagnosed cases each year.
  • The additional or alternative administration of chemotherapy is a particular consideration for women at high risk, although the pertinent clinical trials to date have yielded conflicting evidence on this point.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / therapy. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / therapy. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / therapy. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / therapy. Evidence-Based Medicine. Neoplasms, Hormone-Dependent / diagnosis. Neoplasms, Hormone-Dependent / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemoradiotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dtsch Arztebl Int. 2010 May;107(20):353-9 [20539807.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1510-7 [9809732.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001040 [10796737.001]
  • [Cites] Lancet. 2010 Apr 3;375(9721):1165-72 [20188410.001]
  • [Cites] Lancet. 2010 Mar 6;375(9717):816-23 [20206777.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):788-92 [20065186.001]
  • [Cites] Int J Gynecol Cancer. 2009 Nov;19(8):1465 [19893425.001]
  • [Cites] Obstet Gynecol. 2009 Sep;114(3):523-9 [19701030.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3547-56 [19546404.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(2):CD000402 [19370558.001]
  • [Cites] Obstet Gynecol. 2009 Feb;113(2 Pt 1):319-25 [19155901.001]
  • [Cites] Gynecol Oncol. 2009 Feb;112(2):415-21 [18973934.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):137-46 [19070891.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16 [19033573.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2 Suppl):S101-4 [18804267.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):11-8 [18304622.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18(2):255-61 [17624991.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):226-33 [17996926.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):282-8 [17662377.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):266-71 [16868539.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • [Cites] Curr Opin Obstet Gynecol. 2006 Jun;18(3):245-52 [16735822.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(2):CD003916 [17443533.001]
  • (PMID = 21904591.001).
  • [ISSN] 1866-0452
  • [Journal-full-title] Deutsches Ärzteblatt international
  • [ISO-abbreviation] Dtsch Arztebl Int
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3167060
  •  go-up   go-down


6. Ebert AD, Rosenow G, David M, Mechsner S, Magalov IS, Papadopoulos T: Co-occurrence of atypical endometriosis, subserous uterine leiomyomata, sactosalpinx, serous cystadenoma and bilateral hemorrhagic corpora lutea in a perimenopausal adipose patient taking tamoxifen (20 mg/day) for invasive lobular breast cancer. Gynecol Obstet Invest; 2008;66(3):209-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-occurrence of atypical endometriosis, subserous uterine leiomyomata, sactosalpinx, serous cystadenoma and bilateral hemorrhagic corpora lutea in a perimenopausal adipose patient taking tamoxifen (20 mg/day) for invasive lobular breast cancer.
  • In the cystic ovary (right side), a serous cystadenoma close to a hemorrhagic corpus luteum (HCL) was diagnosed.
  • [MeSH-major] Breast Neoplasms / drug therapy. Cystadenoma, Serous / chemically induced. Endometriosis / chemically induced. Fallopian Tube Diseases / chemically induced. Leiomyoma / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / surgery. Corpus Luteum / drug effects. Corpus Luteum / pathology. Female. Hemorrhage / chemically induced. Humans. Immunohistochemistry. Middle Aged. Ovarian Diseases / chemically induced


7. Wang J, Han N, Wang HL, Zhang ZM, Fan QX: [Therapeutic effect of docetaxel combined with oxaliplatin for treatment of recurrent epithelial ovarian cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov;29(11):2319-20
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic effect of docetaxel combined with oxaliplatin for treatment of recurrent epithelial ovarian cancer].
  • OBJECTIVE: To evaluate the efficacy and safety of docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) for treatment of recurrent epithelial ovarian cancer.
  • METHODS: Thirty-six patients with histologically confirmed recurrent epithelial ovarian cancer received chemotherapy with DTX and OXA.
  • The chemotherapy cycles were repeated every 21 days, and the patients received at least 2 cycles.
  • CONCLUSION: Combination of DTX and OXA produces good therapeutic effect with tolerable toxicity profile for treatment of recurrent epithelial ovarian cancer.
  • [MeSH-major] Cystadenoma, Serous / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenoma, Mucinous / drug therapy. Female. Humans. Middle Aged. Organoplatinum Compounds / administration & dosage. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19923093.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel
  •  go-up   go-down


8. Bieńkiewicz A, Gottwald L, Danilewicz M, Suzin J: [Assessment of the influence of chemotherapy on the nucleolar organizer regions (AgNORs) count in serous ovarian cancer cells]. Ginekol Pol; 2003 Sep;74(9):677-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of the influence of chemotherapy on the nucleolar organizer regions (AgNORs) count in serous ovarian cancer cells].
  • OBJECTIVE: When planning treatment of ovarian cancer, the prognostic factors should be considered.
  • DESIGN: To estimate the influence of chemotherapy on the AgNORs count in serous ovarian cancer cells.
  • MATERIAL AND METHODS: 26 women who underwent surgical procedure and then chemotherapy between 1998-2002 due to serous ovarian cancer were included into the study.
  • In all cases during second-look laparotomy, which was performed after 6 courses of chemotherapy (paclitaxel, cisplatinum), the persistent disease was found.
  • In 17 out of 26 cases it was disseminated neoplasmatic disease.
  • RESULTS: The mAgNOR and pAgNOR mean number before chemotherapy were respectively: 4, 22 +/- 0.94 and 35.62 +/- 19.90.
  • After treatment the mAgNOR and pAgNOR were significantly lower, and the data were respectively: 3.67 +/- 0.91 and 24.15 +/- 19.53.
  • We did not found any correlation between the tendency to change the number of AgNORs and staging, the amount of persistent neoplasmatic tissue, the range of primary surgery, as well as grading.
  • CONCLUSIONS: The number of AgNORs per nucleus in most cases of ovarian cancer after chemotherapy was lower.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / ultrastructure. Nucleolus Organizer Region / drug effects. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / ultrastructure
  • [MeSH-minor] Disease Progression. Female. Humans. Immunohistochemistry. Neoplasm Staging. Time Factors

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674107.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


9. Daponte A, Kostopoulou E, Papandreou CN, Chiotoglou I, Voutsadakis I, Vanakara P, Minas M, Nakou M, Kallitsaris A, Kollia P, Koukoulis G, Messinis IE: Retinoid receptor alpha and Beta expression in serous ovarian tumors. Oncology; 2007;73(1-2):81-9
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoid receptor alpha and Beta expression in serous ovarian tumors.
  • The expression of retinoid acid receptors alpha (RARalpha) and beta (RARbeta) and estrogen receptor alpha (ERalpha) was assessed by immunohistochemistry and Western blotting in normal ovaries, serous cystadenoma (n = 20), serous borderline (n = 14), and serous ovarian cancer (n = 47) and was correlated in cancer cases with stage, grade, progress-free survival (PFS), and survival.
  • RARalpha was increasingly expressed in benign cystadenomas, borderline, and low-stage and advanced-stage neoplasms (p < 0.001).
  • In stage III, G3 serous carcinoma, increased RARalpha expression was an independent prognostic factor associated with lower chemoresponse to first-line chemotherapy (taxol and carboplatin) and shorter PFS (p < 0.002).RARbeta and ERalpha expression did not correlate with RARalpha tumor characteristics or PFS and survival.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cystadenocarcinoma, Serous / chemistry. Cystadenoma, Serous / chemistry. Estrogen Receptor alpha / analysis. Ovarian Neoplasms / chemistry. Receptors, Retinoic Acid / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blotting, Western. CA-125 Antigen / blood. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Radiography, Abdominal. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • [ErratumIn] Oncology. 2010;78(2):124. Papandreou, C N [added]; Voutsadakis, I [added]
  • (PMID = 18334854.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Estrogen Receptor alpha; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor beta
  •  go-up   go-down


10. Hamilton CA, Kapp DS, Chan JK: Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol; 2008 Feb;20(1):26-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical aspects of uterine papillary serous carcinoma.
  • PURPOSE OF REVIEW: We review the demographic and clinicopathologic characteristics, and prognosis of women diagnosed with uterine papillary serous carcinoma, with a focus on clinical management.
  • RECENT FINDINGS: Pathologic evaluation of postmenopausal bleeding is preferred for patients who fit the profile of a high-risk endometrial cancer such as uterine papillary serous carcinoma.
  • Women diagnosed with endometrial cancer who fit this profile and all women with uterine papillary serous carcinoma should undergo comprehensive surgical staging and aggressive cytoreduction of extrauterine disease.
  • Adjuvant therapy remains controversial.
  • Several recent investigations reported on the potential benefit of adjuvant chemotherapy, with many recommending additional loco-regional radiation.
  • SUMMARY: Despite the lack of randomized trials on uterine papillary serous carcinoma, several recent reports have provided insight into the diagnosis, surgical management, and adjuvant treatment of this high-risk endometrial cancer.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenoma, Serous / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197002.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 84
  •  go-up   go-down


11. Dejmek A: Fine needle aspiration cytology of an ovarian luteinized follicular cyst mimicking a granulosa cell tumor. A case report. Acta Cytol; 2003 Nov-Dec;47(6):1059-62
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: In an ovarian cystic aspirate from a 34-year-old woman, the fluid was highly cellular, with a striking predominance of cells interpreted as granulosa cells.
  • Surgery was performed, and histology revealed a benign serous cystadenoma but also numerous maturing follicles and follicular cysts with thick layers of granulosa cells.
  • The aspirate obviously did not represent the cystadenoma but one of the prominent follicular cysts.
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Cell Nucleus / pathology. Cystadenoma, Serous / pathology. Cytoplasm / pathology. Danazol / adverse effects. Diagnosis, Differential. Endometriosis / drug therapy. Estrogen Antagonists / pharmacology. Female. Humans. Ovarian Follicle / pathology. Predictive Value of Tests. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674080.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Antagonists; N29QWW3BUO / Danazol
  •  go-up   go-down


12. Salvia R, Festa L, Butturini G, Tonsi A, Sartori N, Biasutti C, Capelli P, Pederzoli P: Pancreatic cystic tumors. Minerva Chir; 2004 Apr;59(2):185-207
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After the first report by Becourt in 1830, cystic tumors were classified into 2 different types by Compagno and Oertel in 1978: benign tumors with glycogen-rich cells and mucinous cystic neoplasms with overt and latent malignancy.
  • Thanks to the knowledge acquired up to now, a surgical procedure is not always required because the therapeutic choice is conditioned by the correct classification of this heterogeneous group of tumors.
  • Clinical signs are not really useful in the clinical work up, most patients have no symptoms and when clinical signs are present, they may help us to pinpoint the organ of origin but never to identify the type of pathology.
  • Except for inoperable cases due to the critical condition of the patient or non-resectable lesions, surgical treatment differs with the diagnosis.
  • Cystic tumors of the pancreas, therefore, are a heterogeneous group of tumors, with a real problem regarding differential diagnosis between neoplastic and inflammatory lesions.
  • Even with a proper work up, some perplexity may remain about the nature of the lesion and in these cases the surgical procedure has a therapeutic value as well as playing a diagnostic role.
  • The role of surgery is central in the treatment of these tumors because it could be curative when complete resection is possible.
  • In this way, the lack of good therapeutic results with chemotherapy and radiotherapy force the surgeon to go ahead with the procedure.
  • In the last few years the therapeutic approach has changed thanks to new knowledge of the biological behavior of these tumors.
  • In fact, from a surgical approach in all cases, we are now discussing the possibility of a follow-up not only for asymptomatic serous cystadenomas but also for the little branch side intraductal papillary mucinous neoplasms (IPMNs) in critical patients.
  • [MeSH-minor] Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / surgery. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / surgery. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15238892.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng; ita
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 45
  •  go-up   go-down


13. Goldstein NS, Ceniza N: Ovarian micropapillary serous borderline tumors. Clinicopathologic features and outcome of seven surgically staged patients. Am J Clin Pathol; 2000 Sep;114(3):380-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian micropapillary serous borderline tumors. Clinicopathologic features and outcome of seven surgically staged patients.
  • We report the clinicopathologic findings for 7 patients with completely staged ovarian micropapillary serous borderline tumors (MSBTs) to further clarify tumor behavior.
  • Four patients were alive and well at the last follow-up visit, including 1 patient with stage IIIC (lymph node metastases) disease who had noninvasive implants (12 years after surgery).
  • One patient who was free of disease died of complications of chemotherapy and abdominal surgery.
  • Without invasive peritoneal implants, MSBTs seem to behave as similar staged nonmicropapillary serous borderline tumors without invasive peritoneal implants.
  • [MeSH-major] Cystadenoma, Papillary / pathology. Cystadenoma, Serous / secondary. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10989638.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


14. Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B: Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol; 2010 Jun;41(6):794-804
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma.
  • The objective of this study was to analyze the expression and clinical role of this pathway in serous ovarian carcinoma.
  • Higher phospho-AKT Thr308/pan-AKT ratio by Western blotting was associated with more advanced International Federation of Gynecology and Obstetrics stage (P = .018) and a trend for poor response to chemotherapy at first disease recurrence (P = .051).
  • The association between activated AKT and mammalian target of rapamycin expression and clinicopathologic parameters of aggressive disease, including shorter patient survival, provides further evidence regarding the central role of this signaling pathway in ovarian carcinoma.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cystadenoma, Serous / metabolism. Ovarian Neoplasms / metabolism. Protein-Serine-Threonine Kinases / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20153512.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins; 0 / PARK7 protein, human; 0 / Phosphoproteins; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


15. Gungor T, Altinkaya SO, Akbay S, Bilge U, Mollamahmutoglu L: Malign mural nodules associated with serous ovarian tumor of borderline malignancy: a case report and literature review. Arch Gynecol Obstet; 2010 Mar;281(3):485-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malign mural nodules associated with serous ovarian tumor of borderline malignancy: a case report and literature review.
  • BACKGROUND: Cystic tumors of ovary, whether benign, borderline, or malignant may be associated with mural nodule of various types, including sarcomas, sarcoma-like mural nodules (SLMN), and foci of anaplastic carcinoma.
  • Cases of serous borderline ovarian tumor with mural nodules of mixed type are very rare.
  • Left ureter was found to be dilated because of the infiltration of distal part by the tumor, so distal ureteral resection and neoureterocystostomy were performed.
  • Final pathology revealed borderline serous ovarian tumor with mural nodules which were consisted of SLMNs, multiple and sharply demarcated from the adjacent tumor, and sarcomatous nodules showing infiltrative appearance in metastatic regions.
  • She had postoperative chemotherapy and follow-up is going on without metastases in her first year.
  • CONCLUSION: The existence of sarcomatous nodules combined with the SLMN necessitates a careful histologic analysis for treatment and the determination of prognosis.
  • However, too few cases of mixed type mural nodules have been published to warrant a conclusion regarding their prognosis.
  • [MeSH-major] Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597831.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


16. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, Amunni G, Villanucci A, Garbini F, Baroni G, Taddei GL: Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol; 2005 Apr;16(4):590-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma.
  • RESULTS: Gamma/delta T cells are statistically correlated with a brief disease-free interval (P=0.036).
  • CD3 positive tumour-infiltrating T cells are correlated with a brief disease-free interval and with survival (P=0.004 and P=0.0001, respectively).
  • CD3 positive tumour-infiltrating T cells are associated with clinical responsiveness to chemotherapy (P=0.003).
  • CONCLUSIONS: Further studies are required to better understand the role of gamma/delta T cells in ovarian carcinoma, yet these data underline the importance of host immune response to cancer and the need to better study immune mechanisms to modulate the therapeutic treatment of cancer.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699022.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


17. Morowitz M, Huff D, von Allmen D: Epithelial ovarian tumors in children: a retrospective analysis. J Pediatr Surg; 2003 Mar;38(3):331-5; discussion 331-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient age, presenting symptoms, operative procedures, postoperative treatment, and outcome were obtained from the medical record.
  • The histopathologic diagnoses for the epithelial tumors included 9 serous cystadenomas (47%) and 3 mucinous cystadenomas (16%), 3 mucinous cystadenocarcinomas (16%), and 4 serous tumors of borderline malignancy (21%).
  • Two patients (11%) had bilateral disease.
  • Four patients (21%) underwent a subsequent laparotomy for either staging or recurrence, and 2 patients (11%) required chemotherapy.
  • The pediatric surgeon must understand the biologic characteristics, operative management, and follow-up treatment of these tumors, and how these differ from germ cell lesions.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Cystadenocarcinoma, Mucinous / epidemiology. Cystadenoma, Mucinous / epidemiology. Cystadenoma, Serous / epidemiology. Cystectomy. Female. Germinoma / epidemiology. Humans. Hysterectomy. Neoplasms, Multiple Primary / epidemiology. Ovariectomy. Pennsylvania / epidemiology. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA). All rights reserved.
  • (PMID = 12632344.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


18. Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J: Diagnosis and treatment of borderline ovarian neoplasms "the state of the art". Eur J Gynaecol Oncol; 2009;30(5):471-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of borderline ovarian neoplasms "the state of the art".
  • Second cytoreductive surgery is recommended for patients with recurrent disease.
  • Adjuvant postoperative therapy is not indicated in Stage-I diploid tumors.
  • Occasional responses to chemotherapy have been reported in advanced BOTs but no study has shown improved survival.
  • Recently a new theory has been developed describing a subset of S-ovarian cyst adenomas that evolve through S-BOT to low-grade carcinoma.
  • A more correct staging procedure, classification of true serous implants and agreement on the contribution to stage of the presence of gelatinous ascites in mucinous tumours may in the future change the distribution of stage and survival data by stage for women with BOT.
  • Independent prognostic factors in patients with epithelial ovarian BOT without residual tumour after primary surgery are DNA-ploidy, international FIGO-stage, histologic type and patient age.
  • In which group of patients is fertility-sparing surgery advisable and, do patients with borderline tumours benefit from adjuvant treatment?
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / pathology. Cystadenoma, Serous / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Disease Progression. Female. Humans. Neoplasm Staging. Ovariectomy. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899396.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 121
  •  go-up   go-down


19. Camatte S, Morice P, Atallah D, Pautier P, Lhommé C, Haie-Meder C, Duvillard P, Castaigne D: Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg; 2002 Sep;195(3):332-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Forty-two patients were treated for BOT with a procedure that included lymphadenectomy.
  • Thirty-two patients underwent systematic lymphadenectomy, five because of associated cancer (uterine cervix or corpus) and five because of bulky nodes discovered during the surgical procedure.
  • All patients with nodal involvement had serous BOT with peritoneal implants.
  • None of the patients with a mucinous tumor had nodal involvement.
  • None of the patients with early-stage disease (without peritoneal disease) had nodal involvement discovered after routine lymphadenectomy.
  • One patient died of a complication of adjuvant therapy (leukemia after chemotherapy).
  • Routine lymphadenectomy should not be performed in patients with early-stage disease.
  • This procedure should be carried out in patients with serous tumor and enlarged lymph nodes.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Combined Modality Therapy. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / therapy. Cystadenoma, Serous / pathology. Cystadenoma, Serous / therapy. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Neoplasms, Complex and Mixed / pathology. Neoplasms, Complex and Mixed / therapy. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229940.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Leiserowitz GS: Managing ovarian masses during pregnancy. Obstet Gynecol Surv; 2006 Jul;61(7):463-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The specter of a possible malignancy can sway the decision for intervention versus expectant management.
  • The etiologies of ovarian masses are reflective of the patient's age; and, therefore, benign entities such as functional ovarian cysts, benign cystic teratomas, and serous cystadenomas predominate.
  • Morphologic criteria more accurately identify benign cysts compared with malignant tumors.
  • Tumor markers are used primarily to monitor disease status after treatment rather than establish the ovarian tumor diagnosis as a result of lack of specificity, because several markers can be elevated inherent to the pregnancy itself (eg, CA-125, beta-hCG).
  • Although rarely necessary, chemotherapy has been used during pregnancy with minimal fetal toxicity in patients with advanced-stage ovarian cancer in which the risk of maternal mortality outweighs the fetal consequences.


21. McCluggage WG, Strand K, Abdulkadir A: Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer; 2002 Jan-Feb;12(1):62-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metallothioneins (MTs) are a group of low-molecular-weight proteins that are overexpressed in a variety of human neoplasms and are related to differentiation and prognosis in some tumor types.
  • This study investigated immunohistochemically detectable metallothionein expression in benign and malignant ovarian surface epithelial tumors of serous, mucinous, and endometrioid types.
  • Of the malignant tumors, MT expression was found in 68% of endometrioid, 56% of mucinous, and 52% of serous neoplasms.
  • Whether high MT expression is an independent prognostic factor and increased expression indicates chemotherapy resistance in ovarian cancer, as has been previously suggested, should be determined by further studies.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Endometrioid / chemistry. Cystadenocarcinoma, Serous / chemistry. Cystadenoma, Mucinous / chemistry. Cystadenoma, Serous / chemistry. Metallothionein / analysis. Ovarian Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11860537.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9038-94-2 / Metallothionein
  •  go-up   go-down


22. Stankovic Z, Djuricic S, Djukic M, Jovanovic D, Vasiljevic M: Epithelial ovarian tumors and CA125 in premenarchal girls. Eur J Gynaecol Oncol; 2006;27(6):597-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient age, clinical presentation, operative procedures, histologic type of tumor, treatment and outcome were obtained.
  • Histological findings revealed cystadenoma in four girls, one with a mucinous borderline tumor and one with undifferentiated carcinoma.
  • The premenarchal girl with undifferentiated carcinoma in Stage III died after six months in spite of chemotherapy.
  • CA125 is a tumor marker with low sensitivity and specificity for detection of epithelial ovarian malignancy in this age group.
  • [MeSH-major] CA-125 Antigen / blood. Carcinoma / blood. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenoma, Serous / diagnosis. Ovarian Neoplasms / blood
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / blood. Child. Female. Humans. Menarche. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290590.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


23. Chen AP, Zhang J, Liu H, Zhao SP, Dai SZ, Sun XL: [Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Jan;31(1):48-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EGFR positive expression rate in stage III-IV carcinoma tissues, poor differentiation and with ascites was higher than that in stage I-II carcinomas of well differentiation and without ascites (P < 0.05).
  • The effective rate of chemotherapy in patients with EGFR and LRP-positive expression were 57.1% and 53.7%, respectively, significantly lower than that in cases with EGFR and LRP-negative expression (85.0% and 90.9%, P < 0.05).
  • The survival time was shorter in the cases with EGFR and LRP-positive expression, poor differentiation, ascites and chemoresistance (P < 0.01), and only LRP-positive expression and chemotherapeutic effect were independently related to survival time (P < 0.05).
  • EGFR and LRP-positive expression are related to chemoresistance, and detection of the two proteins may be helpful in guiding chemotherapy choice for ovarian cancer.
  • [MeSH-major] Drug Resistance, Neoplasm. Neovascularization, Pathologic / pathology. Ovarian Neoplasms / blood supply. Receptor, Epidermal Growth Factor / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Antigens, CD34 / metabolism. Ascites / pathology. Cystadenocarcinoma, Mucinous / blood supply. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / blood supply. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Mucinous / blood supply. Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / blood supply. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Drug Resistance, Multiple. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538870.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


24. Skírnisdóttir I, Sorbe B: Body mass index as a prognostic factor in epithelial ovarian cancer and correlation with clinico-pathological factors. Acta Obstet Gynecol Scand; 2010;89(1):101-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SETTING: Patients with EOC, who underwent primary surgery and postoperative chemotherapy in the Orebro Medical Region, Sweden, 1994-2003.
  • SAMPLE: A total of 446 patients with stage I-IV EOC, who underwent primary surgery and chemotherapy with information of values of height and weight at the start of chemotherapy were eligible.
  • Among patients with serous tumors a significant (p = 0.01) worse survival was found in the subgroup of underweight (BMI < 18.5) patients compared with patients in the other BMI groups.
  • The prognostic impact of BMI on survival was only noted for underweight patients with serous tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / physiopathology. Chi-Square Distribution. Cystadenoma, Mucinous / mortality. Cystadenoma, Mucinous / physiopathology. Cystadenoma, Serous / mortality. Cystadenoma, Serous / physiopathology. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Multivariate Analysis. Overweight / epidemiology. Prognosis. Proportional Hazards Models. Retrospective Studies. Thinness


25. Nagai Y, Kishimoto T, Nikaido T, Nishihara K, Matsumoto T, Suzuki C, Ogishima T, Kuwahara Y, Hurukata Y, Mizunuma M, Nakata Y, Ishikura H: Squamous predominance in mixed-epithelial papillary cystadenomas of borderline malignancy of mullerian type arising in endometriotic cysts: a study of four cases. Am J Surg Pathol; 2003 Feb;27(2):242-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous predominance in mixed-epithelial papillary cystadenomas of borderline malignancy of mullerian type arising in endometriotic cysts: a study of four cases.
  • Mixed-epithelial papillary cystadenoma of borderline malignancy of mullerian type (MEBMM) is composed of a mixture of mullerian epithelial types, such as mucinous, serous, endometrioid, and squamous.
  • In one of those three cases, there was no recurrence after undergoing surgery only; in the other two of those three cases, there was no recurrence after undergoing surgery and receiving postoperative chemotherapy.
  • The tumors were mainly composed of a proliferation of squamous-type epithelium, with minor foci containing a mixture of other mullerian-type epithelia, especially mucinous.
  • [MeSH-major] Cystadenoma, Papillary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12548172.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Bondiau PY, Largillier R, Foa C, Rasendrarijao D, Frenay M, Gérard JP: [Treatment of brain metastasis from ovarian cancer]. Cancer Radiother; 2003 Jun;7(3):184-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of brain metastasis from ovarian cancer].
  • [Transliterated title] Traitement des métastases cérébrales du cancer de l'ovaire.
  • We present here the case of a patient treated for an ovarian cancer by surgery and chemotherapy.
  • Three months after the end of chemotherapy, the patient developed cerebral metastases from ovarian carcinoma (CMOC) treated by iterative surgery and and whole brain irradiation.
  • CMOC can occur during or after adjuvant chemotherapy and the best management strategies to better define determinants of survival for patients are not well known.
  • It appears that a better outcome of CMOC may be obtained by an aggressive treatment, if possible, including surgery, radiotherapy, and chemotherapy.
  • Taking into account the increase in the incidence of the CMOC and their early occurrence, some authors have proposed a prophylactic brain radiotherapy in patients who receive adjuvant chemotherapy.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Cystadenoma, Serous / secondary. Cystadenoma, Serous / therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / blood. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Female. France / epidemiology. Headache / etiology. Humans. Magnetic Resonance Imaging. Metrorrhagia / etiology. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12834774.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CA-125 Antigen; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Iervolino P, Palmieri M, Rotondi M, D'Alessandro P, Iuliano R: [Borderline ovarian tumors. Retrospective analysis of 20 cases]. Minerva Ginecol; 2001 Feb;53(1 Suppl 1):97-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minimal requirements for conservative management were adequate staging and complete information about the therapeutic options.
  • Factors important in the choice of the treatment were, age, wish to preserve fertility, histologic type and grade, and the stage of the tumour.
  • Thirteen (65%) were with mucinous cystadenoma of borderline malignancy, 7 cases (35%) were of serous type.
  • Any patient were treated with chemotherapy after operation.
  • With a median follow up of two years, we observed no recurrence of carcinoma in women treated conservatively or in those treated more radically.
  • CONCLUSIONS: Conservative surgery remains a therapeutic option in selected patients with borderline ovarian tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11526732.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


28. Zuntová A, Sumerauer D, Teslík L, Kabícková E, Koutecký J: [Mixed germ cell tumours of the ovary in childhood and adolescence]. Cesk Patol; 2004 Jul;40(3):92-101
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mixed germ cell tumours of the ovary are rare malignant neoplasms containing combinations of two or more types of germ cell elements.
  • The aim of the study was to review biopsy examinations, medical records, treatment strategy, follow-up and outcome of all girls treated for mixed germ cell tumour of the ovary at the Department of Pediatric Oncology, University Hospital Motol during the period 1979-2002.
  • The clinical data on surgical treatment, chemotherapy and radiotherapy used and follow-up information were obtained in all girls.
  • All girls presented with unilateral tumour of the ovary and all underwent surgery as an initial treatment.
  • The original diagnosis of mixed histology was confirmed in all cases; in five cases the tumour contained three histologic components, in eleven cases the tumour consisted of two germ cell types.
  • At the time of diagnosis three patients had stage I disease, four patients stage II, seven stage III and two stage IV disease.
  • All patients were treated with chemotherapy after surgery, predominantly with platinum-based regimens (PVB, BEP).
  • In seven girls with advanced disease treated in the early years, radiotherapy was administered to the pelvis or whole abdomen.
  • Overall survival and event-free survival were 80% and 81.3% respectively (median follow-up time 7.6 years).
  • Three patients have died from the disease, two progressed on treatment (MAC), one girl relapsed three months after finishing therapy, no further therapy was administered.
  • Histology showed mixed serous and mucinous cystadenoma.
  • Microscopic examination should be extensive and careful to find out all types of malignant germ cell elements.
  • Platinum based chemotherapy is effective in the management of children and adolescents with mixed germ cell tumors of the ovary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493415.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


29. Chudecka-Głaz A, Rzepka-Górska I: Favorable effects of long-term therapy with gonadoliberin analogues in three patients with advanced and recurrent ovarian cancer. Eur J Gynaecol Oncol; 2009;30(5):589-91
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable effects of long-term therapy with gonadoliberin analogues in three patients with advanced and recurrent ovarian cancer.
  • A 32-year-old patient with a primary highly advanced ovarian cancer received standard therapy and additional implants with GnRH analogues as consolidation therapy for 20 months.
  • In a 56-year-old patient with advanced ovarian cancer GnRH analogues were used as consolidation therapy for seven years, achieving seven years of a complete clinical remission and nine and a half years of survival up to now.
  • CONCLUSION: It seems that gonadoliberin analogues should find their place in ovarian cancer therapy.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Cystadenoma, Serous / drug therapy. Gonadotropin-Releasing Hormone / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899425.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down






Advertisement